Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2015 | original article | Ausgabe 1-2/2015

Wiener klinische Wochenschrift 1-2/2015

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 1-2/2015
Autoren:
MD Dominik Riss, MD Johannes Pammer, MD, MME Matthaeus C. Grasl, MSc Alexandra Kaider, MD Sven Schneider, MD, PD Boban M. Erovic

Summary

Purpose

To investigate the role of desmocollin 3 expression in radiation sensitivity and survival in squamous cell carcinoma of the head and neck.

Methods

Tissue samples of 40 patients undergoing primary radiotherapy were stained for desmocollin 3, a transmembrane desmosomal protein. The protein expression was determined by immunohistochemistry. A retrospective chart review was performed to assess overall survival, radiation sensitivity, and disease-free interval.

Results

18 of 40 patients showed desmocollin 3 immunoreactivity. 78 % (14/18) showed radiation sensitivity in the desmocollin 3 positive group, whereas 59 % (13/22) underwent remission in the desmocollin 3 negative group (p = 0.2). The median overall and disease-free survival time was 21 and 26 months, respectively. Univariate and multivariable Cox regression models revealed no statistically significant hazard ratios.

Conclusion

In this cohort of squamous cell carcinoma of the head and neck, we found no evidence for a predictive potential of desmocollin 3.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2015

Wiener klinische Wochenschrift 1-2/2015Zur Ausgabe

mitteilungen der gesellschaft

ÖGIM Flip